BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 16959520)

  • 1. [The French preliminary experience of the use of a seed-projector for exclusive iodine 125 prostate brachytherapy: feasibility and acute toxicity].
    Pommier P; Delannes M; LeFloch O; Bernier V; Baron MH; Thomas L; Malet C; Bonnet J; Louisot P; Aletti P; Goubard O; Chemin A; Chirat F; Lebivic S; Montbarbon X; Bachaud JM; Votron L; Lasbareilles O; Desmettre O; Bringeon G; Gassa F; Peiffert D
    Cancer Radiother; 2006 Dec; 10(8):559-64. PubMed ID: 16959520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors predicting for urinary morbidity following 125iodine transperineal prostate brachytherapy.
    Williams SG; Millar JL; Duchesne GM; Dally MJ; Royce PL; Snow RM
    Radiother Oncol; 2004 Oct; 73(1):33-8. PubMed ID: 15465143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and physical determinants for toxicity of 125-I seed prostate brachytherapy.
    Wust P; von Borczyskowski DW; Henkel T; Rosner C; Graf R; Tilly W; Budach V; Felix R; Kahmann F
    Radiother Oncol; 2004 Oct; 73(1):39-48. PubMed ID: 15465144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preimplant predictive factors of urinary retention after iodine 125 prostate brachytherapy.
    Mabjeesh NJ; Chen J; Stenger A; Matzkin H
    Urology; 2007 Sep; 70(3):548-53. PubMed ID: 17905113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Four-year experience of interstitial permanent brachytherapy for Japanese men with localized prostate cancer.
    Ishiyama H; Satoh T; Kitano M; Tsumura H; Kotani S; Okusa H; Uemae M; Baba S; Hayakawa K
    Jpn J Clin Oncol; 2008 Jul; 38(7):469-73. PubMed ID: 18577509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severity categories of the International Prostate Symptom Score before, and urinary morbidity after, permanent prostate brachytherapy.
    Gutman S; Merrick GS; Butler WM; Wallner KE; Allen Z; Galbreath RW; Adamovich E
    BJU Int; 2006 Jan; 97(1):62-8. PubMed ID: 16336330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients.
    Keyes M; Miller S; Moravan V; Pickles T; McKenzie M; Pai H; Liu M; Kwan W; Agranovich A; Spadinger I; Lapointe V; Halperin R; Morris WJ
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1023-32. PubMed ID: 19111402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. (125)I monotherapy using D90 implant doses of 180 Gy or greater.
    Kao J; Stone NN; Lavaf A; Dumane V; Cesaretti JA; Stock RG
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):96-101. PubMed ID: 17980505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypofractionated boost with high-dose-rate brachytherapy and open magnetic resonance imaging-guided implants for locally aggressive prostate cancer: a sequential dose-escalation pilot study.
    Ares C; Popowski Y; Pampallona S; Nouet P; Dipasquale G; Bieri S; Ozsoy O; Rouzaud M; Khan H; Miralbell R
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):656-63. PubMed ID: 19250768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy.
    Zelefsky MJ; Nedelka MA; Arican ZL; Yamada Y; Cohen GN; Shippy AM; Park JJ; Zaider M
    Brachytherapy; 2008; 7(1):1-6. PubMed ID: 18299108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Favorable toxicity and biochemical control using real-time inverse optimization technique for prostate brachytherapy.
    Raben A; Rusthoven KE; Sarkar A; Glick A; Benge B; Jacobs D; Raben D
    Brachytherapy; 2009; 8(3):297-303. PubMed ID: 19213608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Brachytherapy for localised prostate cancer].
    Peiffert D
    Cancer Radiother; 2007 Nov; 11(6-7):373-8. PubMed ID: 17962060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Permanent prostate implant using high activity seeds and inverse planning with fast simulated annealing algorithm: A 12-year Canadian experience.
    Martin AG; Roy J; Beaulieu L; Pouliot J; Harel F; Vigneault E
    Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):334-41. PubMed ID: 17084553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Side effects of permanent I125 prostate seed implants in 667 patients treated in Leeds.
    Bottomley D; Ash D; Al-Qaisieh B; Carey B; Joseph J; St Clair S; Gould K
    Radiother Oncol; 2007 Jan; 82(1):46-9. PubMed ID: 17161481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Technical acquisition and dosimetric assessment of iodine-125 permanent brachytherapy in localized prostate cancer: our first series of 100 patients.
    Tanaka N; Asakawa I; Kondo H; Tanaka M; Fujimoto K; Hasegawa M; Konishi N; Hirao Y
    Int J Urol; 2009 Jan; 16(1):70-4. PubMed ID: 19120529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience.
    Lee B; Shinohara K; Weinberg V; Gottschalk AR; Pouliot J; Roach M; Hsu IC
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1106-12. PubMed ID: 17197119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial comparison of inverse optimization, modified peripheral technique, and geometric optimization as real-time intraoperative computer planning options for permanent seed implantation of the prostate.
    Raben A; Sammons S; Sim S; Chen H; Hanlon A; Sarkar A; Donavanik V; Grebler A; Geltzeiler J; Benge B; Glick A; Jacob D; Koprowski P
    Brachytherapy; 2007; 6(4):238-45. PubMed ID: 17991621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Physical basics and clinical realization of interstitial brachytherapy of the prostate with iodine 125].
    Kaulich TW; Lamprecht U; Paulsen F; Kahmann F; Maurer U; Henkel TO; Loeser W; Bichler KH; Nüsslin F; Bamberg M
    Strahlenther Onkol; 2002 Oct; 178(10):548-55. PubMed ID: 12386786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer.
    Zelefsky MJ; Yamada Y; Cohen GN; Shippy A; Chan H; Fridman D; Zaider M
    Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):65-70. PubMed ID: 17189063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brachytherapy for prostate cancer: is the pretreatment prostate volume important?
    Meyer JP; Bell CR; Elwell C; Kunkler RB
    BJU Int; 2008 Dec; 102(11):1585-8. PubMed ID: 18990138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.